drugset / Trial / NCT05569655
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
RandomizedParallel-groupOpen-labelTreatment
Summary
Efficacy and safety evaluation of tolvaptan in the treatment of patients with right heart failure caused by pulmonary arterial hypertension
Timeline
- Start
- 2021-04-06
- Primary completion
- 2022-11-30
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tolvaptan | Unknown | 15 mg | — |
| Background | Furosemide | Other / unclassified | 20 mg | — |
| Background | Furosemide | Other / unclassified | 40 mg | — |